Mark Buzza

Head of Research, Innovation and Advocacy at Pancare Foundation

[Mark Buzza @MarkBuzza]

@StartupShelley Congratulations Michelle and team. Fantastic news! Well done.

[Mark Buzza @MarkBuzza]

@VCCCAlliance Fantastic opportunity to join the @VCCCAlliance Research team. Please let me know if you have any questions.

[Mark Buzza @MarkBuzza]

@asxlongtail This is sensational Chris. Well done. I know you have been thinking about and working passionately on this for a long time. Congrats on this huge milestone - such great news!

[Nature Reviews Urology @NatRevUrol]

We are really excited to continue our long-term collaboration with Movember with the Movember Prostate Cancer Landscape Analysis #NewInNRU and FREE to access https://t.co/RRJsx0a1v6. With special thanks to @MarkBuzza for his hard work! @MovemberUK @MovemberAUS @Movember

[Mark Buzza @MarkBuzza]

Very pleased to be taking on a new challenge and joining the @VicCompCancerCr from mid-July. Looking forward to working with key stakeholders and a fantastic team to deliver benefits for cancer patients and their families.

[VCCC Alliance @VCCCAlliance]

ANNOUNCEMENT | Dr @MarkBuzza to lead #VCCC #ClinicalResearch into new chapter of growth & development.

Mark's strategic insights & experience will significantly contribute to #VCCCalliance impact in Victoria's clinical #CancerResearch.

Read more >>> https://t.co/WOkTTeunuI

[Mark Buzza @MarkBuzza]

@declangmurphy @MovemberAUS @CancerAustralia @pros_tic @PeterMacCC @EJWFoundation @Epworth @DrMHofman @AzadOncology @gu_onc @AnnetteVDHeyden Congrats Declan and team. Terrific milestone.

[Declan Murphy @declangmurphy]

We are pleased to have our first patient on #LuTectomy trial - LuPSMA prior to robotic prostatectomy. Part of our #UpFront PSMA grant thanks to @MovemberAUS @CancerAustralia @pros_tic @PeterMacCC @EJWFoundation @Epworth https://t.co/56bgOJV9JC

[ANZUP @ANZUPtrials]

Congrats @DrMHofman on #ASCO20 #TheraP @ANZUPtrials oral presentation. More men with mCRPC had PSA decline >50% with Lu-PSMA vs cabazitaxel (66% vs 37%). Well done to all involved @PCFA @MovemberAUS @ANSTO @adacap_news @TrialsCentre @gentlemansride @CancerAustralia @PeterMacCC

[Mark Buzza @MarkBuzza]

@ANZUPtrials @DrMHofman @PCFA @MovemberAUS @ANSTO @adacap_news @TrialsCentre @gentlemansride @CancerAustralia @PeterMacCC Congratulations @DrMHofman and the entire research team on a fantastic trial and a great collaborative effort. So great to see the #TheraP results in the public domain. Well done to all.

[ANZUP @ANZUPtrials]

#TheraP @ANZUPtrials #ASCO20 abstract live. More men with mCRPC had PSA reduction >50% with Lu-PSMA vs cabazitaxel (66% vs 37%). Oral presentation 29 May. Congrats to all @DrMHofman @PCFA @MovemberAUS @ANSTO @adacap_news @TrialsCentre @gentlemansride @CancerAustralia @PeterMacCC

[Mark Buzza @MarkBuzza]

A wonderful example of PSMA theranostics in action! Congratulations to the research team on a fantastic collaborative effort.

[ANZUP @ANZUPtrials]

#TheraP @ANZUPtrials #ASCO20 abstract live. More men with mCRPC had PSA reduction >50% with Lu-PSMA vs cabazitaxel (66% vs 37%). Oral presentation 29 May. Congrats to all @DrMHofman @PCFA @MovemberAUS @ANSTO @adacap_news @TrialsCentre @gentlemansride @CancerAustralia @PeterMacCC

[Mark Buzza @MarkBuzza]

@TelixPharma @MovemberAUS Thanks so much for your ongoing support Chris!! Amazing as always and loving the Mo!

[Mark Buzza @MarkBuzza]

Very pleased to be presenting our prostate cancer research investment strategy and lessons learned from running global collaborative programs at @VicCompCancerCr on Monday 23rd September #MonLunchLive @MovemberAUS

[VCCC Alliance @VCCCAlliance]

Disrupting #medicalresearch funding & the collective impact approach. #MonLunchLive 23 Sep 1-2pm, Dr @MarkBuzza @MovemberAUS on lessons learned running global programs. Register today > https://t.co/UbagVK2uX8

[VCCC Alliance @VCCCAlliance]

Disrupting #medicalresearch funding & the collective impact approach. #MonLunchLive 23 Sep 1-2pm, Dr @MarkBuzza @MovemberAUS on lessons learned running global programs. Register today > https://t.co/UbagVK2uX8

[VCCC Alliance @VCCCAlliance]

Hear from @MarkBuzza Director, Global Biomedical Research Programs @MovemberAUS on disrupting the established #medicalresearch funding model. #MonLunchLive 23 Sep, 1-2pm, register to attend or watch via webinar > https://t.co/UbagVK2uX8

[Prostate PIONEER @ProstatePioneer]

Unbiased independent scientific & ethical advice will be critical over the lifetime of PIONEER. WP1 have established an independent Scientific & Ethical Advisory Board of key opinion leaders in prostate cancer to guide PIONEER over the 5 years @ttopstart @NDowJames @devecserizs

[Movember Australia @MovemberAUS]

New ways of treating prostate cancer could be available within 5 years, following an announcement today that scientists will receive a $12M funding boost from the Aus Government and Movember.
Supported by @SVHSydney, @PeterMacCC, @unimelb and @GregHuntMP.
https://t.co/5g2bXLnOXk

[Kathy Connell @connell_kathy]

Look who’s here at ⁦@MTGT_Challenge⁩ ⁦@medtechactuator⁩ gala in #Melbourne tonight? Great to connect with ⁦@MovemberAUS⁩ @MarkBuzza⁩ & ⁦@StartupShelley⁩ Always great to make new connections! ⁦@JNJInnovation⁩

[Prostate PIONEER @ProstatePioneer]

PIONEER internal website (deliverable D1.2) is fully functional allowing for effective and quick communication between all consortium members @ttopstart @NDowJames. For more info see our project website https://t.co/0wuRfjhuWh

[Kathy Connell @connell_kathy]

Calling all 🇦🇺🇳🇿 #biotechs attending #jpm19 conference in #SanFrancisco - check this out! @AusBiotech @biomelb @LSQld @MTPConnect_AUS @BIOTechNZ @AdvanceQld @VicGovAu @JobsforNSW @ChiefSciWA @ChiefSciAdvisor